RxDoctor Payments Data

Philip Couch

Psychiatric/Mental Health · Pinehurst, NCNPI 1215380035

Payments from drug & device makers

$1,537in general payments, 2019–2025

Across 81 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$632
  • Idorsia Pharmaceuticals US Inc$250
  • Corium, LLC$162
  • Alkermes, Inc.$132
  • Vanda Pharmaceuticals Inc.$80
  • Supernus Pharmaceuticals, Inc.$77
  • plus $204 from 8 others

What the payments were for

  • Food & beverage$1,537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,537 in reported general payments places this provider in the 70th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$29,805
Medicare patients
28
Services billed
306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LybalviOlanzapine/Samidorphan Malate12$18,486
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine34$1,528
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine48$1,091
Bupropion XlBupropion Hcl28$956
Fluvoxamine Maleate26$900
Buspirone Hcl82$760
Hydroxyzine Hcl31$647
Duloxetine Hcl41$611
Quetiapine Fumarate39$552
Temazepam11$548
Divalproex Sodium ErDivalproex Sodium16$492
Paroxetine Hcl12$359
Gabapentin46$327
Bupropion Hcl SrBupropion Hcl32$296
Doxepin Hcl16$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Lybalvi$132$18,48612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →